Vérification…
Traduit automatiquement. Doses et mises en garde : vérifiez l'original en anglais. Lire en anglais
Accueil / Enregistré au Nigeria / Pagenax 120 mg/mL Solution for Injection

Pagenax 120 mg/mL Solution for Injection

NAFDAC REG NO: A6-100100 Médicament

Enregistré auprès de NAFDAC. Enregistrement actifAs of 16 November 2026 · synced automatically from official sources.
Produit
Pagenax 120 mg/mL Solution for Injection
Numéro NAFDAC
A6-100100
Principe actif
Brolucizumab
Dosage
120 mg/mL
Forme
Solution for intravitreal injection
Conditionnement
1 x 0.23 mL (in vial/pre-filled syringe)
Fabricant
Non répertorié
Déposant / Titulaire :
Novartis Nigeria Limited
Approuvé
2 Apr 2023
Statut
Actif Vue sur NAFDAC ↗
Enregistrement valable jusqu'au
29 Mar 2028
Alertes OMS
Non trouvé
Community reports
None
Times checked
0

About the medicine: Brolucizumab: uses, dosage and brands worldwide

What we found

  • Pagenax 120 mg/mL Solution for Injection is on the NAFDAC register with an active registration (A6-100100). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generated automatically from the NAFDAC register, WHO alerts and community data as of today. This is not medical advice. Always follow your doctor or pharmacist.

How to use Pagenax 120 mg/mL Solution for Injection

Ce que dit la notice officielle. Si un médecin vous l'a prescrit, suivez l'ordonnance. La notice de votre boîte prime si elle est différente.

Pour qui

BEOVU ® is indicated for the treatment of: BEOVU is a human vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of: Neovascular (Wet) Age-Related Macular Degeneration (AMD) ( 1.1 ) Diabetic Macular Edema (DME) ( 1.2 ) 1.1 Neovascular (Wet) Age-related Macular Degeneration (AMD) 1.2 Diabetic Macular Edema (DME)

Comment le prendre et à quelle fréquence
  • Neovascular (Wet) Age-Related Macular Degeneration (AMD) The recommended dose for BEOVU is 6 mg (0.05 mL of 120 mg/mL solution) monthly (approximately every 25-31 days) for the first three doses, followed by one dose of 6 mg (0.05 mL) every 8-12 weeks
  • Diabetic Macular Edema (DME) The recommended dose for BEOVU is 6 mg (0.05 mL of 120 mg/mL solution) every six weeks (approximately every 39-45 days) for the first five doses, followed by one dose of 6 mg (0.05 mL of 120 mg/mL solution) every 8-12 weeks
  • General Dosing Information For ophthalmic intravitreal injection
  • BEOVU must be administered by a qualified physician
  • BEOVU is available packaged as follows [see How Supplied/Storage and Handling ] : Pre-filled Syringe Vial kit with injection components (vial, filter needle) Neovascular (Wet) Age-Related Macular Degeneration (AMD) The recommended dose for BEOVU is 6 mg (0.05 mL of 120 mg/mL solution) administered by intravitreal injection monthly (approximately every 25 to 31 days) for the first three doses, followed by 6 mg (0.05 mL) by intravitreal injection once every 8 to 12 weeks
  • Diabetic Macular Edema (DME) The recommended dose for BEOVU is 6 mg (0.05 mL of 120 mg/mL solution) administered by intravitreal injection every six weeks (approximately every 39-45 days) for the first five doses, followed by 6 mg (0.05 mL) by intravitreal injection once every 8-12 weeks
  • Preparation for Administration – Pre-filled Syringe and Vial Store BEOVU in the refrigerator between 2°C to 8°C (36°F to 46°F); do not freeze. …
Strengths it comes in

BEOVU is a clear to slightly opalescent and colorless to slightly brownish-yellow solution available as: Intravitreal injection: 6 mg/0.05 mL in a single-dose pre-filled syringe. Intravitreal injection: 6 mg/0.05 mL in a single-dose vial. Intravitreal injection: 6 mg/0.05 mL solution in a single-dose pre-filled syringe ( 3 ). …

Children
  • The safety and efficacy of BEOVU
  • In pediatric patients has not been established
Older adults

In the two Phase 3 clinical studies in AMD, approximately 90% (978/1089) of patients randomized to treatment with BEOVU were ≥ 65 years of age and approximately 60% (648/1089) were ≥ 75 years of age. In the two Phase 3 clinical studies in DME, approximately 45% (164/368) of patients randomized to treatment with BEOVU were ≥ 65 years of age and approximately 10% (37/368) were ≥ 75 years of age. …

While you are taking it
  • Advise patients that in the days following BEOVU administration, patients are at risk of developing endophthalmitis, retinal detachment, retinal vasculitis and/or retinal vascular occlusion
  • If the eye becomes red, sensitive to light, painful, or if a patient develops any change in vision, instruct the patient to seek immediate care from an ophthalmologist [see Warnings and Precautions ]
  • Patients may experience temporary visual disturbances after an intravitreal injection with BEOVU and the associated eye examination [see Adverse Reactions ]
  • Advise patients not to drive or use machinery until visual function has recovered sufficiently. …
Talk to a doctor first if
  • Ocular or Periocular Infections Active Intraocular Inflammation Hypersensitivity Ocular or Periocular Infections BEOVU is contraindicated in patients with ocular or periocular infections
  • Active Intraocular Inflammation BEOVU is contraindicated in patients with active intraocular inflammation
  • Hypersensitivity BEOVU is contraindicated in patients with known hypersensitivity to brolucizumab or any of the excipients in BEOVU. …
Warnings

Endophthalmitis and retinal detachment may occur following intravitreal injections. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay ( 5.1 ). Retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation, have been reported following BEOVU injections. Patients should be instructed to report any change in vision without delay ( 5.2 ). Increases in intraocular pressure (IOP) have been seen within 30 minutes of an intravitreal injection ( 5.3 ). There is a potential risk of arterial thromboembolic events (ATE) following intravitreal use of VEGF inhibitors ( 5.4 ). …

Effets secondaires possibles

The following potentially serious adverse reactions are described elsewhere in the labeling: Hypersensitivity [see Contraindications (4.3)] Endophthalmitis and Retinal Detachment [see Warnings and Precautions (5.1)] Retinal Vasculitis and/or Retinal Vascular Occlusion [see Warnings and Precautions (5.2)] Increase in Intraocular Pressure [see Warnings and Precautions (5.3)] Thromboembolic Events [see Warnings and Precautions (5.4)] The most common adverse reactions reported in patients receiving BEOVU are vision blurred, cataract, conjunctival hemorrhage, eye pain, and vitreous floaters ( 6.1 ). …

Pregnancy and breastfeeding

8.1 Pregnancy Risk Summary There are no adequate and well-controlled studies of BEOVU administration in pregnant women. In an animal reproduction study, intravitreal administration of brolucizumab to pregnant monkeys once every 4 weeks in one eye from organogenesis to birth did not indicate any harmful effects with respect to pre- or postnatal development at 10-fold the maximum recommended human dose (MRHD) on a mg/kg basis ( see Data ). …

En cas d'oubli

Prenez-le dès que vous y pensez, sauf s'il est presque l'heure de la dose suivante. Dans ce cas, sautez la dose oubliée. Ne prenez jamais deux doses à la fois pour compenser. Vérifiez votre notice, certains médicaments font exception.

From the official U.S. FDA label for this active ingredient. Your pack may have a different strength, so always read its leaflet. If a doctor prescribed it, follow the prescription. Ask a pharmacist if you are unsure. Label dated 2026-10-26.

Label for brolucizumab, the active ingredient registered with NAFDAC.

Check your pack of Pagenax 120 mg/mL Solution for Injection

Add the expiry date on your pack for a full Trust Score.

Ou prenez la boîte en photo
Encore 3 vérifications gratuites aujourd'hui Official sources: U.S. FDA · EMA (EU) · Health Canada · WHO alerts

About Pagenax 120 mg/mL Solution for Injection

What is in Pagenax 120 mg/mL Solution for Injection?

Pagenax 120 mg/mL Solution for Injection contains Brolucizumab (120 mg/mL), as solution for intravitreal injection, according to its NAFDAC registration record.

Is Pagenax 120 mg/mL Solution for Injection registered with NAFDAC?

Yes. Pagenax 120 mg/mL Solution for Injection is listed on the NAFDAC register under registration number A6-100100, and its registration is active as of 16 November 2026.

Has Pagenax 120 mg/mL Solution for Injection been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Pagenax 120 mg/mL Solution for Injection in our automatically synced alert list.

How can I check that my pack of Pagenax 120 mg/mL Solution for Injection is genuine?

Run a free authenticity scan with the NAFDAC number A6-100100, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

How do I take Pagenax 120 mg/mL Solution for Injection?

Follow your prescription or the leaflet in your pack. The official label says: Neovascular (Wet) Age-Related Macular Degeneration (AMD) The recommended dose for BEOVU is 6 mg (0.05 mL of 120 mg/mL solution) monthly (approximately every 25-31 days) for the first three doses, followed by one dose of 6 mg (0.05 mL) every 8-12 weeks ( 2.2 ). Diabetic Macular Edema (DME) The recommended dose for BEOVU is 6 mg (0.05 mL of 120 mg/mL solution) every six weeks (ap…

What is Pagenax 120 mg/mL Solution for Injection used for?

BEOVU ® is indicated for the treatment of: BEOVU is a human vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of: Neovascular (Wet) Age-Related Macular Degeneration (AMD) ( 1.1 ) Diabetic Macular Edema (DME) ( 1.2 ) 1.1 Neovascular (Wet) Age-related Macular Degeneration (AMD) 1.2 Diabetic Macular Edema (DME) (Summarised from the official U.S. FDA label for brolucizumab. Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Pagenax 120 mg/mL Solution for Injection? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from PillVera users, not medical advice. Report side effects to your doctor and to NAFDAC.